CCS
SUPN icon

Crosspoint Capital Strategies’s Supernus Pharmaceuticals SUPN Stock Holding History

Crosspoint Capital Strategies’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-89,277
Closed -$3.85M – 164
2017
Q2 		$3.85M Buy
+89,277
New +$3.18M 3.36% 3

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Crosspoint Capital Strategies's SUPN Position: Q3 2017 in Review

Crosspoint Capital Strategies sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 89,277 shares — an estimated $3.85M sold.

Crosspoint Capital Strategies first reported a position in SUPN in Q2 2017 and held it in 1 quarter. The position peaked at $3.85M in Q2 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Crosspoint Capital Strategies reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 89,277 Supernus Pharmaceuticals shares in Q3 2017, an estimated $3.85M.
  • Crosspoint Capital Strategies first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Supernus Pharmaceuticals position peaked at $3.85M in Q2 2017.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2017, filed 6 Nov 2017.